

the authority for ICCVAM involvement in activities relevant to the development of alternative test methods. ICCVAM acts to ensure that new and revised test methods are validated to meet the needs of federal agencies, increase the efficiency and effectiveness of federal agency test method review, and optimize utilization of scientific expertise outside the federal Government. Additional information about ICCVAM can be found at <http://ntp.niehs.nih.gov/go/iccvam>.

NICEATM administers ICCVAM, provides scientific and operational support for ICCVAM-related activities, and conducts and publishes analyses and evaluations of data from new, revised, and alternative testing approaches. NICEATM and ICCVAM work collaboratively to evaluate new and improved testing approaches applicable to the needs of U.S. federal agencies. NICEATM and ICCVAM welcome the public nomination of new, revised, and alternative testing approaches for validation studies and technical evaluations. Additional information about NICEATM can be found at <http://ntp.niehs.nih.gov/go/niceatm>.

Dated: April 13, 2017.

**John R. Bucher,**

*Associate Director, National Toxicology Program.*

[FR Doc. 2017-08354 Filed 4-24-17; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Cancer Institute; Cancellation of Meeting

Notice is hereby given of the cancellation of the National Cancer Institute Special Emphasis Panel, May 1, 2017, 8:00 a.m. to May 2, 2017, 1:00 p.m., Hyatt Regency Bethesda, One Bethesda Metro Center, 7400 Wisconsin Avenue, Bethesda, MD 20814 which was published in the **Federal Register** on March 22, 2017, 82 FR 54.

This meeting is being amended to cancel the meeting on May 1-2, 2017.

Dated: April 20, 2017.

**Melanie J. Pantoja,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2017-08348 Filed 4-24-17; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Government-Owned Inventions; Availability for Licensing

**AGENCY:** National Institutes of Health, HHS.

**ACTION:** Notice.

**SUMMARY:** The inventions listed below are owned by an agency of the U.S. Government and are available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

#### FOR FURTHER INFORMATION CONTACT:

Chris Kornak, 240-627-3705, [chris.kornak@nih.gov](mailto:chris.kornak@nih.gov). Licensing information and copies of the U.S. patent applications listed below may be obtained by communicating with the indicated licensing contact at the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852; tel. 301-496-2644. A signed Confidential Disclosure Agreement will be required to receive copies of unpublished patent applications.

#### SUPPLEMENTARY INFORMATION:

Technology description follows.

#### A Second CD4-Binding Region of HIV-1 gp120 Critical for Viral Infectivity: New Methods for Treatment and Vaccine Development

*Description of Technology:* It is believed that immunization with an effective immunogen based on the HIV-1 envelope glycoprotein can elicit a neutralizing antibody response, which may be protective against HIV-1 infection. NIAID researchers have discovered a new critical component of the CD4-binding site in gp120, named CD4-BS2, which is exclusively formed in the trimeric envelope conformation. It was further found that this newly recognized region is critical for the progression of the fusogenic mechanism that leads to HIV-1 entry and infection of the cells. This discovery may lead to new methods of treatment, for treating HIV-1, as well as to the production of new vaccine immunogens.

This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as well as for further

development and evaluation under a research collaboration.

*Potential Commercial Applications:* New target for HIV therapeutic and vaccine development.

*Competitive Advantages:* A new molecular target discovered in this invention may facilitate the development of next-generation HIV therapeutics and vaccines.

*Development Stage:* Proof-of-concept studies demonstrate that CD4 binding to CD4-BD2 is critical for triggering gp120 conformational changes that enable coreceptor binding and HIV-1 infectivity. Animal studies are ongoing.

*Inventors:* Paolo Lusso, NIAID, NIH; and Qingbo Liu, NIAID, NIH.

*Publications:* Liu, Qingbo, et al. "Quaternary contact in the initial interaction of CD4 with the HIV-1 envelope trimer." *Nature Structural & Molecular Biology* (2017).

*Intellectual Property:* HHS Reference No. E-230-2015/0—U.S. Patent Application No. 62/292,750 filed 02/08/2016; PCT Application No. PCT/US2017/017038 filed 02/08/2017.

*Licensing Contact:* Chris Kornak, 240-627-3705, [chris.kornak@nih.gov](mailto:chris.kornak@nih.gov).

*Collaborative Research Opportunity:* The Technology Transfer and Intellectual Property Office (TTIPO) is seeking parties interested in collaborative research to further co-develop HIV-1 vaccines and/or inhibitors that target the newly recognized region. For collaboration opportunities, please contact Chris Kornak, 240-627-3705, [chris.kornak@nih.gov](mailto:chris.kornak@nih.gov).

Dated: April 10, 2017.

**Suzanne Frisbie,**

*Deputy Director, Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases.*

[FR Doc. 2017-08351 Filed 4-24-17; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute on Aging; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial